Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
Gen Lin,Zhijie Wang,Qian Chu,Yi Hu,Dingzhi Huang,Jun Wang,Fan Yang,Wenzhao Zhong,Chengzhi Zhou,Bo Zhu,Xinghao Ai,Baoshan Cao,Yabing Cao,Mingqiu Chen,Xiaohui Chen,Tianqing Chu,Jianchun Duan,Yun Fan,Yong Fang,Shuitu Feng,Weineng Feng,Hui Guo,Chengbo Han,Yong He,Shaodong Hong,Jie Hu,Meijuan Huang,Yan Huang,Da Jiang,Kan Jiang,Richeng Jiang,Bo Jin,Shi Jin,Jisheng Li,Min Li,Ziming Li,Chao Li,Jie Lin,Anwen Liu,Si‐Yang Maggie Liu,Liu Yutao,Zhefeng Liu,Zhe Liu,Zhenhua Liu,Zhentian Liu,Zhigang Liu,Yuping Lu,Tangfeng Lv,Zhiyong Ma,Qian Miao,Min Peng,Xingxiang Pu,Xiu Bao Ren,Jianzhen Shan,Jinlu Shan,Peng Shen,Bo Shen,Meiqi Shi,Yong Song,Zhengbo Song,ChunXia Su,Jianguo Sun,Panwen Tian,Jinliang Wang,Feng Wang,Huijuan Wang,Jialei Wang,Qian Wang,Wenxian Wang,Yan Wang,Lin Wu,Fang Wu,Yang Xia,Congying Xie,Conghua Xie,Tao Xin,Jianping Xiong,Haipeng Xu,Song Xu,Yiquan Xu,Bin Xu,Chunwei Xu,Xiaolong Yan,Zhenzhou Yang,Wenxiu Yao,Yao Yu,Ye Feng,Zongyang Yu,Yongfeng Yu,Dongsheng Yue,Haibo Zhang,HongMei Zhang,Li Zhang,Longfeng Zhang,Qiuyu Zhang,Tongmei Zhang,Bicheng Zhang,Jun Zhao,Mingfang Zhao,Xiaobin Zheng,Qiaofeng Zhong,Jin Zhou,Penghui Zhou,Zhengfei Zhu,Juntao Zou,Zihua Zou
DOI: https://doi.org/10.1111/1759-7714.15209
IF: 3.223
2024-01-16
Thoracic Cancer
Abstract:Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD‐1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.
oncology,respiratory system